In the past week, RNAC stock has gone down by -8.33%, with a monthly gain of 34.88% and a quarterly surge of 17.93%. The volatility ratio for the week is 14.29%, and the volatility levels for the last 30 days are 11.23% for Cartesian Therapeutics Inc The simple moving average for the past 20 days is 13.72% for RNAC’s stock, with a 3.13% simple moving average for the past 200 days.
Is It Worth Investing in Cartesian Therapeutics Inc (NASDAQ: RNAC) Right Now?
Company’s 36-month beta value is 0.64.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAC is 8.79M, and currently, short sellers hold a 23.40% ratio of that floaft. The average trading volume of RNAC on October 11, 2024 was 105.54K shares.
RNAC) stock’s latest price update
Cartesian Therapeutics Inc (NASDAQ: RNAC)’s stock price has gone decline by -5.85 in comparison to its previous close of 22.22, however, the company has experienced a -8.33% decrease in its stock price over the last five trading days. zacks.com reported 2024-10-04 that Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Analysts’ Opinion of RNAC
Oppenheimer gave a rating of “Outperform” to RNAC, setting the target price at $50 in the report published on June 04th of the current year.
RNAC Trading at 32.32% from the 50-Day Moving Average
After a stumble in the market that brought RNAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.89% of loss for the given period.
Volatility was left at 11.23%, however, over the last 30 days, the volatility rate increased by 14.29%, as shares surge +30.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.34% upper at present.
During the last 5 trading sessions, RNAC fell by -8.33%, which changed the moving average for the period of 200-days by -2.38% in comparison to the 20-day moving average, which settled at $18.40. In addition, Cartesian Therapeutics Inc saw 1.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAC starting from SPRINGER TIMOTHY A, who purchase 119,906 shares at the price of $19.89 back on Oct 03 ’24. After this action, SPRINGER TIMOTHY A now owns 7,943,465 shares of Cartesian Therapeutics Inc, valued at $2,384,713 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Cartesian Therapeutics Inc, purchase 80,301 shares at $22.58 during a trade that took place back on Oct 04 ’24, which means that SPRINGER TIMOTHY A is holding 8,023,766 shares at $1,813,010 based on the most recent closing price.
Stock Fundamentals for RNAC
Current profitability levels for the company are sitting at:
- -3.13 for the present operating margin
- 0.95 for the gross margin
The net margin for Cartesian Therapeutics Inc stands at -9.84. The total capital return value is set at -0.28. Equity return is now at value -49.79, with -111.40 for asset returns.
Based on Cartesian Therapeutics Inc (RNAC), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -5.58. The debt to equity ratio resting at -0.09. The interest coverage ratio of the stock is -40.04.
Currently, EBITDA for the company is -84.88 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 15.71. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.78.
Conclusion
In a nutshell, Cartesian Therapeutics Inc (RNAC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
